Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
A Phase 2, Multicenter, Randomized, Double-Blind Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia (AGA) Analyzed by Biopsy of the Scalp Prior To and Post Dosing
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1020
mi
from
Lynchburg, VA
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
A Phase 2, Multicenter, Randomized, Double-Blind Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia (AGA) Analyzed by Biopsy of the Scalp Prior To and Post Dosing
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1020
mi
from
Lynchburg, VA
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Arizona Arthritis & Rheumatology Research PLLC
861
mi
from
Phoenix, AZ
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Arizona Arthritis & Rheumatology Research PLLC
861
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Baptist Health Center for Clinical Research
368
mi
from
Little Rock, AR
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Baptist Health Center for Clinical Research
368
mi
from
Little Rock, AR
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Arthritis Associates of Southern California
1178
mi
from
Los Angeles, CA
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Arthritis Associates of Southern California
1178
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
UCLA David Geffen School of Medicine
1168
mi
from
Los Angeles, CA
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
UCLA David Geffen School of Medicine
1168
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Georgetown University Hospital
1127
mi
from
Washington,
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Georgetown University Hospital
1127
mi
from
Washington,
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Northwestern University
611
mi
from
Chicago, IL
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Northwestern University
611
mi
from
Chicago, IL
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Heartland Research Associates, LLC
32
mi
from
Wichita, KA
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Heartland Research Associates, LLC
32
mi
from
Wichita, KA
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Central Kentucky Research Associates, Inc.
731
mi
from
Lexington, KY
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Central Kentucky Research Associates, Inc.
731
mi
from
Lexington, KY
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
1148
mi
from
Baltimore, MD
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
1148
mi
from
Baltimore, MD
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Boston University Medical Center
1444
mi
from
Boston, MA
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Boston University Medical Center
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
West Michigan Rheumatology
739
mi
from
Grand Rapids, MI
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
West Michigan Rheumatology
739
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
The Center for Pharmaceutical Research, P.C.
193
mi
from
Kansas City, MO
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
The Center for Pharmaceutical Research, P.C.
193
mi
from
Kansas City, MO
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Robert Wood Johnson Medical School
1263
mi
from
New Brunswick, NJ
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Robert Wood Johnson Medical School
1263
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Hospital for Special Surgery
1289
mi
from
New York, NY
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Hospital for Special Surgery
1289
mi
from
New York, NY
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
1052
mi
from
Durham, NC
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
1052
mi
from
Durham, NC
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic
898
mi
from
Cleveland, OH
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic
898
mi
from
Cleveland, OH
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
1223
mi
from
Philadelphia, PA
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
1223
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh
973
mi
from
Pittsburgh, PA
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh
973
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated:  12/31/1969
University of Texas- Houston Medical School
572
mi
from
Houston, TX
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Status: Enrolling
Updated: 12/31/1969
University of Texas- Houston Medical School
572
mi
from
Houston, TX
Click here to add this to my saved trials
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated:  12/31/1969
Stanford University
1329
mi
from
Palo Alto, CA
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated: 12/31/1969
Stanford University
1329
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated:  12/31/1969
John Hopkins Scleroderma Center
1148
mi
from
Baltimore, MD
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated: 12/31/1969
John Hopkins Scleroderma Center
1148
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated:  12/31/1969
Boston University Medical Center
1444
mi
from
Boston, MA
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated: 12/31/1969
Boston University Medical Center
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated:  12/31/1969
Rutgers University
1263
mi
from
New Brunswick, NJ
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated: 12/31/1969
Rutgers University
1263
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated:  12/31/1969
Weill-Cornell Medical College
1289
mi
from
New York, NY
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated: 12/31/1969
Weill-Cornell Medical College
1289
mi
from
New York, NY
Click here to add this to my saved trials
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center
974
mi
from
Pittsburgh, PA
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center
974
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated:  12/31/1969
University of Utah
777
mi
from
Salt Lake City, UT
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated: 12/31/1969
University of Utah
777
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated:  12/31/1969
Arthritis Association of Southern CA
1168
mi
from
Los Angeles, CA
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated: 12/31/1969
Arthritis Association of Southern CA
1168
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated:  12/31/1969
University of Texas- Houston Medical School
572
mi
from
Houston, TX
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
Status: Enrolling
Updated: 12/31/1969
University of Texas- Houston Medical School
572
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up
Status: Enrolling
Updated:  12/31/1969
Altman Dermatology Associates
601
mi
from
Arlington Heights, IL
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up
Status: Enrolling
Updated: 12/31/1969
Altman Dermatology Associates
601
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
Status: Enrolling
Updated:  12/31/1969
Long Island Skin Cancer and Dermatologic Surgery
1327
mi
from
Smithtown, NY
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
Status: Enrolling
Updated: 12/31/1969
Long Island Skin Cancer and Dermatologic Surgery
1327
mi
from
Smithtown, NY
Click here to add this to my saved trials
Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up
Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up
Status: Enrolling
Updated:  12/31/1969
Laser & Skin Surgery Center of Indiana
647
mi
from
Carmel, IN
Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up
Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up
Status: Enrolling
Updated: 12/31/1969
Laser & Skin Surgery Center of Indiana
647
mi
from
Carmel, IN
Click here to add this to my saved trials
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1344
mi
from
New Haven, CT
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1344
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1320
mi
from
Miami, FL
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1320
mi
from
Miami, FL
Click here to add this to my saved trials
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1444
mi
from
Boston, MA
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1444
mi
from
Boston, MA
Click here to add this to my saved trials
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
852
mi
from
Clinton Township, MI
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
852
mi
from
Clinton Township, MI
Click here to add this to my saved trials
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
558
mi
from
Fridley, MN
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
558
mi
from
Fridley, MN
Click here to add this to my saved trials
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
552
mi
from
Minneapolis, MN
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
976
mi
from
Winston-Salem, NC
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
976
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
895
mi
from
Cleveland, OH
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
895
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1383
mi
from
Portland, OR
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1383
mi
from
Portland, OR
Click here to add this to my saved trials
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
522
mi
from
Austin, TX
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
522
mi
from
Austin, TX
Click here to add this to my saved trials
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
569
mi
from
Houston, TX
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
569
mi
from
Houston, TX
Click here to add this to my saved trials
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1181
mi
from
Norfolk, VA
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1181
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
683
mi
from
Birmingham, AL
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
683
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
349
mi
from
Hot Springs, AR
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
349
mi
from
Hot Springs, AR
Click here to add this to my saved trials
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1329
mi
from
Trumbull, CT
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1329
mi
from
Trumbull, CT
Click here to add this to my saved trials
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1454
mi
from
Beverly, MA
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1454
mi
from
Beverly, MA
Click here to add this to my saved trials
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
884
mi
from
Fort Gratiot, MI
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
884
mi
from
Fort Gratiot, MI
Click here to add this to my saved trials
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
561
mi
from
Katy, TX
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
561
mi
from
Katy, TX
Click here to add this to my saved trials